Top Markets
#1 Black Phoenix Black Phoenix +736.78%
#2 Beam Beam +33.31%
#3 SAFEcoin SAFEcoin +19.80%
#4 THORChain THORChain +18.15%
#5 Tutorial Tutorial +17.03%
#6 Bless Bless +15.48%
#7 TENDIES TENDIES +15.42%
#8 EfficientFrontier EfficientFrontier +15.28%
#9 THORChain Yield THORChain Yield +13.62%
#10 Versatize Coin Versatize Coin +12.49%
Coin of the day
Black Phoenix Black Phoenix
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Rapport Therapeutics, Inc. Common Stock Rapport Therapeutics, Inc. Common Stock

Rapport Therapeutics, Inc. Common Stock

RAPP
Rang in Aktien #5670
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical... Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
Aktienkurs
$52.78
Zuletzt synchronisiert: 2026-08-26
Marktkapitalisierung
$2.52B
Veränderung (1 Tag)
3.14%
Veränderung (1 Jahr)
252.56%
Land
US
Handel Rapport Therapeutics, Inc. Common Stock (RAPP)

Kategorie

Healthcare
Dividendenhistorie für Rapport Therapeutics, Inc. Common Stock (RAPP)
Rapport Therapeutics, Inc. Common Stock (Aktienkürzel: RAPP) zahlte insgesamt 0 Dividenden.
Die Summe aller Dividenden (angepasst an Aktiensplits) beträgt: 0.00
Dividendenrendite (TTM): 0
Dividendenzahlungen für Rapport Therapeutics, Inc. Common Stock (RAPP) von 2026 bis 2026
Jährliche Dividendenzahlungen
Jahr Dividende (angepasst an Aktiensplits) ändert
Nicht genügend Daten für die angegebenen Daten.
Liste aller Dividendenzahlungen
Jahr Dividende ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenzahlungen ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Dividendenzahlungen Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH